Takahashi, Yutaka http://orcid.org/0000-0002-1337-9246
Biller, Beverly M. K. http://orcid.org/0000-0003-4359-4622
Fukuoka, Hidenori
Ho, Ken K. Y. http://orcid.org/0000-0002-2508-9588
Rasmussen, Michael Højby http://orcid.org/0000-0002-2210-0366
Nedjatian, Navid http://orcid.org/0000-0002-0290-9803
Sværke, Claus
Yuen, Kevin C. J. http://orcid.org/0000-0002-8169-2728
Johannsson, Gudmundur http://orcid.org/0000-0003-3484-8440
Clinical trials referenced in this document:
Documents that mention this clinical trial
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
https://doi.org/10.1007/s11102-022-01283-3
Documents that mention this clinical trial
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
https://doi.org/10.1007/s11102-022-01283-3
Documents that mention this clinical trial
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
https://doi.org/10.1007/s11102-022-01283-3
Funding for this research was provided by:
Novo Nordisk
Article History
Accepted: 7 October 2022
First Online: 15 November 2022
Declarations
:
: YT has received honoraria from Novo Nordisk, Novartis, Eli Lilly, Recordati Rare Disease, Otsuka Pharma and Ascendis Pharma and has received grant support from Ono Pharma, Teijin Pharma, Novo Nordisk, Kowa Pharma, Taisho Pharma, Daiichi Sankyo Pharma and Tanabe Mitsubishi Pharma. BMKB has served as the PI of grants to Massachusetts General Hospital over the last 3 years from: Ascendis, Crinetics, Ionis, Millendo, Novartis and Strongbridge and has been an occasional consultant over the last 3 years to Aeterna Zentaris, Ascendis, Crinetics, HRA Pharma, Ipsen, EMD Serono, Novartis, Novo Nordisk, Recordati, Sparrow, Strongbridge and Xeris. HF declares no funding for this paper. KH serves as an advisor to Novo Nordisk and Ipsen. MHR is an employee of and stockholder in Novo Nordisk. NN is an employee of Novo Nordisk. CS is an employee of and stockholder in Novo Nordisk. KY has received research grants to Barrow Neurological Institute from Ascendis, Crinetics, Amryt and Corcept. Served as an occasional advisory board member for Novo Nordisk, Ascendis, Sandoz, Corcept, Ipsen, Amryt, Strongbridge, Crinetics, Xeris and Recordati. Served as occasional speaker for Novo Nordisk, Recordati and Corcept. GJ has received lecture fees from Merck Serono, Novartis, Novo Nordisk, Otsuka, Pfizer, and Sandoz, as well as consultancy fees from Astra Zeneca, Novo Nordisk and Shire.
: All procedures involving human participants performed in these studies were in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki.
: REAL 1, REAL 2 and REAL Japan were approved by the relevant local and national ethics committees, and conducted with written consent from all patients in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice.